<DOC>
	<DOCNO>NCT01214850</DOCNO>
	<brief_summary>The purpose trial evaluate effect Novartis Vaccine 's Meningococcal vaccine carriage Neisseria meningitidis young adult population .</brief_summary>
	<brief_title>Novartis Vaccine Diagnostics Carriage Trial</brief_title>
	<detailed_description />
	<mesh_term>Vaccines</mesh_term>
	<criteria>Healthy subject , 1824 year age provide write informed consent time enrollment ; Subjects available visit schedule study ; Subjects good health determine outcome medical history , physical examination clinical judgment investigator . History serogroup B meningococcal vaccine administration ; Current previous , confirm suspected disease cause N. meningitidis ; Household contact and/or intimate exposure individual laboratory confirm N. meningitidis infection within 60 day enrollment ; Significant acute chronic infection within previous 7 day fever ( defined oral temperature ≥38ºC ) within previous day ; Antibiotics within 3 day ( 72 hour ) prior enrollment ; Pregnancy nursing ( breastfeed ) mother ; Females childbearing age use plan use acceptable birth control measure , 12 month duration study . Oral , inject implanted hormonal contraceptive , diaphragm , condom , intrauterine device sexual abstinence consider acceptable form birth control . If sexually active subject must use one accepted birth control method least 30 day prior study entry ; Any serious chronic progressive disease ( e.g. , neoplasm , diabetes , cardiac disease , hepatic disease , progressive neurological disease seizure disorder ; autoimmune disease , human immunodeficiency virus ( HIV ) infection acquire immunodeficiency syndrome ( AIDS ) , blood dyscrasia diathesis , sign cardiac renal failure severe malnutrition ) ; Known suspected impairment/alteration immune system , immunosuppressive therapy , include use corticosteroid immunosuppressive dos chronic use inhale highpotency corticosteroid within previous 60 day . [ Use topical corticosteroid administer study limited area ( i.e. , eczema knee face elbow ) body allow ] ; use immunostimulants ; Receipt blood , blood product and/or plasma derivative , parenteral immunoglobulin preparation within previous 90 day ; History severe allergic reaction previous vaccination hypersensitivity vaccine component ; Participation another clinical trial within last 90 day plan study ; Family member household member research staff ; Any condition opinion investigator and/or Regional MD may interfere evaluation study objective .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>24 Years</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>Meningococcal vaccine</keyword>
	<keyword>Meningococcal B</keyword>
	<keyword>Meningococcal ACWY serogroups</keyword>
</DOC>